Form 4: AIM ImmunoTech CEO Acquires 60,110 Shares in Open Market Purchase

AIM ImmunoTech's CEO, Thomas K Equels, purchased 60,110 shares of common stock at $0.183 per share on November 20, 2024.

Summary

• Thomas K Equels, CEO and President of AIM ImmunoTech Inc., acquired 60,110 shares of the company's common stock on November 20, 2024.
• The shares were purchased at a price of $0.183 per share.
• Following this transaction, Mr. Equels directly owns 1,552,968 shares of AIM ImmunoTech common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be seen as a positive signal, but this is a routine transaction and not a major event.

Positives

• The CEO's purchase of shares may indicate confidence in the company's future prospects.
• The purchase increases the CEO's direct stake in the company.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders make transactions in their company's stock. It is a routine disclosure required by law.

Comparison to Industry Standards

• Insider trading activity is common across all publicly listed companies.
• Form 4 filings are a standard part of regulatory compliance for company executives and directors.
• The size of this transaction is not unusual for a CEO of a company of this size.

Stakeholder Impact

• The share purchase may be viewed positively by shareholders as it indicates confidence from the CEO.

Key Dates

Keywords

AIM ImmunoTech, insider trading, share purchase, CEO, Thomas K Equels, stock acquisition, common stock